Gan & Lee Pharmaceuticals. (SHA:603087)

China · Delayed Price · Currency is CNY

69.20

+2.86 (4.31%)

Sep 14, 2026, 3:00 PM CST

Market Cap	41.19B -6.2%
Revenue (ttm)	4.21B +10.8%
Net Income	1.15B +25.0%
EPS	1.94 +25.3%
Shares Out	595.20M
PE Ratio	35.67
Forward PE	25.72
Dividend	1.00 (1.42%)
Ex-Dividend Date	May 29, 2026

Volume	6,356,509
Open	65.95
Previous Close	66.34
Day's Range	65.91 - 69.50
52-Week Range	51.51 - 82.25
Beta	0.27
Analysts	Strong Buy
Price Target	72.50 (+4.77%)
Earnings Date	Aug 26, 2026

About SHA:603087

Gan & Lee Pharmaceuticals., a biopharmaceutical company, engages in the development, production, and commercialization of insulin analogs and medical devices in China. Its products include Basalin, an insulin glargine injection; Prandilin, an insulin lispro injection; Prandilin 25, an insulin lispro mix 75/25 injection; Rapilin, an insulin aspart injection; Rapilin 30, an insulin aspart 30 injection; and Similin 30, a mixed protamine human insulin injection. The company also offers GanleePen, an insulin injection device; and GanleeFine, an insu... [Read more]

Industry Medical Instruments & Supplies

Sector Healthcare

Founded 1998

Employees 5,309

Stock Exchange Shanghai Stock Exchange

Ticker Symbol 603087

Full Company Profile

Financial Performance

In 2025, SHA:603087's revenue was 4.05 billion, an increase of 33.06% compared to the previous year's 3.05 billion. Earnings were 1.14 billion, an increase of 86.05%.

Financial Statements

Analyst Summary

According to 3 analysts, the average rating for 603087 stock is "Strong Buy." The 12-month stock price target is ¥72.50, which is an increase of 4.77% from the latest price.

Price Target

¥72.50

(4.77% upside)

Analyst Consensus: Strong Buy

Stock Forecasts